The primary Non-Hodgkin’s central nervous system lymphoma

Česká verze

Authors: J. Búřil ¹; A. Pokorná ²; P. Búřilová ²
Authors place of work: I. neurologická klinika LF MU a FN u sv. Anny v Brně ¹; Katedra ošetřovatelství a porodní asistence, LF MU, Brno ²
Published in the journal: Cesk Slov Neurol N 2020; 83(1): 105-107
Category: Dopisy redakci
doi: https://doi.org/10.14735/amcsnn2019105

Zdroje

1. Szumera-Cieckiewicz A, Galazka K, Szpor J et al. Distribution of lymphomas in Poland ccording to World Health Organization classification: analysis of 11718 cases from National Histopathological Lymphoma Register project – the Polish Lymphoma Research Group study. Int J Clin Exp Pathol 2014; 7(6): 3280–3286.

2. Issa DE, Van den Schans SAM, Chamuleau MED et al. Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands. Hematologica 2015; 100(4): 525–533. doi: 10.3324/haematol.2014.107300.

3. Ichikawa Y, Maeda M, Ishida M et al. Unusual MRI fi ndings in primary central nervous system lymphoma presenting diff use linear enhancements located in the perivascular space. J Neurol 2006; 256: 1094–1096.

4. Ambler, Z. Lymfomatózní neuropatie (neurolymfomatóza) – kazuistika. Cesk Slov Neurol N 2010; 73/106(6): 725–727.

5. Nabhan C, Byrtek M, Rai A et al. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United

States. Br J Hematol 2015; 170(1): 85–95. doi 10.1111/bjh.13399.

6. Swerdlow SH, Campo E, Pileri SA et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127(20): 2375–2390. doi: 10.1182/blood-2016-01-643569.

7. Report NZIS 09/2016. Ústav zdravotnických informací a statistiky ČR. [online]. Dostupné z URL: http://www.uzis.cz/katalog/zdravotnicka-statistika.

8. Lenz G, Wright GW, Emre NC et al. Molecular subtypes od diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008; 105 (36): 13520–13525. doi: 10.1073/pnas.0804295105.

9. Ghielmini M, Vitolo U, Kimby E et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol 2013; 24: 561–576. doi: 10.1093/annonc/mds517.

10. Peyrade F, Jardin F, Thieblemont C et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011; 12(5): 460–468. doi: 10.1016/S1470-2045(11)70069-9.